Sucharu Prakash, MD
Medical Oncology · Paris, TXNPI 1184667628
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $83,478 of the $124,517 with a category attached, or 67.0%. Myriad Genetic Laboratories, Inc. accounts for 74.9% of it on its own, with 34 other manufacturers making up the rest. Reporting peaked in 2021 at $63,486 and has fallen 98.9% since, to $700 in 2025.
Across 170 payments — averaging $732.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Myriad Genetic Laboratories, Inc.$93K
- AstraZeneca$10K
- Rigel Pharmaceuticals, Inc.$4K
- Karyopharm Therapeutics Inc.$2K
- Seagen Inc.$2K
- Array Biopharma Inc$2K
- plus $12K from 29 others
Across 465 payments — averaging $2058.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$227K
- Eli Lilly$198K
- E.r. Squibb & Sons, L.L.C.$168K
- Amgen$109K
- Eisai Inc.$82K
- Janssen Research & Development, LLC$35K
- plus $139K from 9 others
What the payments were for
- Consulting fees$83,47867%
- Speaking & faculty fees$28,03423%
- Travel & lodging$7,7746%
- Food & beverage$4,7534%
- Education$4790%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Myriad Genetic Laboratories, Inc. | 86 | $93,236 |
| AstraZeneca | 7 | $9,796 |
| Rigel Pharmaceuticals, Inc. | 7 | $3,975 |
| Karyopharm Therapeutics Inc. | 1 | $2,250 |
| Seagen Inc. | 5 | $1,842 |
| Array Biopharma Inc | 2 | $1,591 |
| Beigene USA, Inc. | 2 | $1,313 |
| Epizyme, Inc. | 1 | $1,250 |
| Bristol Myers Squibb | 3 | $1,238 |
| Exelixis Inc. | 1 | $1,225 |
| Pharmaessentia USA Corporation | 2 | $1,100 |
| Daiichi Sankyo Inc. | 2 | $1,055 |
| Bayer | 1 | $900 |
| G1 Therapeutics, Inc. | 3 | $778 |
| EMD Serono, Inc. | 1 | $500 |
| Beigene, Ltd. | 1 | $450 |
| Astellas Pharma US Inc | 5 | $370 |
| Pharmacyclics LLC, An Abbvie Company | 6 | $257 |
| AbbVie | 5 | $209 |
| Tempus AI, Inc | 5 | $166 |
| GSK | 2 | $153 |
| Jazz Pharmaceuticals Inc. | 1 | $149 |
| Puma Biotechnology, Inc. | 2 | $147 |
| E.r. Squibb & Sons, L.L.C. | 6 | $126 |
| Tesaro, Inc. | 1 | $124 |
| Pfizer | 1 | $123 |
| Pharming Healthcare, Inc. | 2 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $33 |
| Myovant Sciences Inc. | 1 | $24 |
| Genentech USA, Inc. | 1 | $19 |
| Abbott | 1 | $14 |
| Novartis | 1 | $14 |
| Incyte Corporation | 1 | $14 |
| Gilead | 1 | $12 |
| Secura Bio, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- myChoice CDx$46,650
- myRisk$13,325
- EndoPredict$12,577
- BRAC CDx$10,982
- BRACAnalysis$5,628
- Tavalisse$3,889
- TAGRISSO$2,800
- PreciseTumor$2,781
- XPOVIO$2,250
- IMFINZI$2,220
- BRAFTOVI$1,575
- TAZVERIK$1,250
- Cabometyx$1,225
- BESREMI$1,100
- Vitrakvi$900
- COSELA$778
- LYNPARZA$555
- Tepmetko$500
- BRUKINSA$450
- XOSPATA$250
How this compares
$124,517 in reported general payments places this provider in the 85th percentile of 495 medical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 59 | $842,236 |
| CalquenceAcalabrutinib Maleate | 47 | $701,620 |
| RevlimidLenalidomide | 25 | $438,534 |
| PomalystPomalidomide | 26 | $429,871 |
| XtandiEnzalutamide | 28 | $388,530 |
| OrserduElacestrant Hcl | 16 | $356,897 |
| InlytaAxitinib | 19 | $350,857 |
| ImbruvicaIbrutinib | 12 | $227,648 |
| JaypircaPirtobrutinib | 17 | $190,867 |
| JakafiRuxolitinib Phosphate | 12 | $188,622 |
| ErleadaApalutamide | 13 | $186,280 |
| MektoviBinimetinib | 13 | $185,718 |
| BraftoviEncorafenib | 12 | $172,905 |
| Abiraterone Acetate | 47 | $32,774 |
| EliquisApixaban | 16 | $9,168 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Beigene USA, Inc.Brukinsa | $1,313 | $842,23659 claims |
| AstraZenecaCalquence | $9,796 | $701,62047 claims |
| Bristol Myers SquibbRevlimid | $1,238 | $438,53425 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $126 | $429,87126 claims |
| Astellas Pharma US IncXtandi | $370 | $388,53028 claims |
| PfizerInlyta, Eliquis | $123 | $360,02535 claims |
| Array Biopharma IncMektovi, Braftovi | $1,591 | $358,62325 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $257 | $227,64812 claims |
| Incyte CorporationJakafi | $14 | $188,62212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 495 medical oncology providers in Texas.
Other medical oncology in Paris
- Moshe LevyDallas$5.1M
- Suresh RatnamMcAllen$3M
- Roy HerbstHouston$1.9M
- Andrew WhiteleyDallas$1.7M
- Eric NadlerDallas$1.6M
- Vijay GunugantiSan Antonio$1.5M
- Sue EckhardtAustin$1.5M
- Joyce O'ShaughnessyDallas$1.3M
- Ronan KellyDallas$1.1M
- Maen AbdelrahimHouston$999K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.